Losartan: investigation of contamination with possible carcinogen

The ongoing European Medicines Agency review of contaminated valsartan has been extended to include candesartan, irbesartan, losartan and olmesartan.
The ongoing European Medicines Agency review of contaminated valsartan has been extended to include candesartan, irbesartan, losartan and olmesartan.